Denali Therapeutics shares are trading higher after B. Riley Securities initiated coverage on the stock with a Buy rating and $38 price target.
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has initiated coverage on Denali Therapeutics with a Buy rating and a price target of $38. This has led to an increase in the trading of Denali Therapeutics shares.
September 06, 2023 | 5:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics' stock is trading higher following B. Riley Securities' initiation of coverage with a Buy rating and a $38 price target.
The initiation of coverage by B. Riley Securities with a Buy rating and a price target of $38 indicates a positive outlook for Denali Therapeutics. This has led to increased trading of the company's shares, suggesting a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100